Incretin franchise trades price for volume as US net pricing resets

Incretin franchise trades price for volume as US net pricing resets

Healthcare, biotech & life sciences · Sector 06 (rank 2 of 25) · T-06-01
Score 94.0/100 · Evidence factor 0.90 · Confidence high · triangulated · Last verified 2026-09-15

In one sentence. Tirzepatide and semaglutide remain the largest revenue engine in pharmaceuticals, but the unit economics changed in 2026.

Why it matters

The single largest profit pool in the sector is now being expanded by volume and compressed by price at the same time, and the two effects are not landing evenly on the two incumbents. Anyone modelling pharma revenue, payer budgets, or US healthcare inflation off 2024-25 GLP-1 price assumptions is working from a stale base.

What is happening

Tirzepatide and semaglutide remain the largest revenue engine in pharmaceuticals, but the unit economics changed in 2026. Eli Lilly reported Q2 2026 revenue of roughly $23bn, up 48%, and raised full-year guidance to $85-87bn. Novo Nordisk, over the same quarter, guided to flat-to-minus-6% full-year sales after a January warning of a 4-12% decline, with management publicly defending the economics of a lower-priced oral product. The November 2025 most-favoured-nation agreement set TrumpRx cash prices at about $350/month for injectables and from $150/month for orals, and a $245/month Medicare and Medicaid price with a $50 copay.

First observable signal. Novo Nordisk's profit warning and guidance cut (2026-01) followed by the November 2025 White House MFN agreement with Lilly and Novo; visible in Q1 2026 results (2026-05-06).

Evidence

Where sources disagree

• Novo Nordisk 2026 full-year sales guidance — Novo Nordisk January 2026 warning as reported by Pharmaceutical Technology: sales dip warning; shares fell 18% vs BioPharma Dive, 2026-08-05: revised to flat or -6% from a prior -4% to -12% range. Likely reason: Sequential revisions across three reporting dates rather than a genuine conflict; the January figure is the trough guidance and the August figure reflects better-than-expected oral uptake.

Companies and products

Companies. Eli Lilly, Novo Nordisk, Pfizer, Amgen, AstraZeneca, CSPC Pharmaceutical Group
Products. Mounjaro / Zepbound (tirzepatide), Ozempic / Wegovy (semaglutide), oral Wegovy, Foundayo (orforglipron), CagriSema
Funding. Not venture-funded; capital flows are corporate capex — Lilly $27bn and Novo Nordisk $10bn additional US manufacturing commitments tied to the November 2025 MFN agreement.

Impact

Industry. Beneficiaries: Eli Lilly, patients gaining cash-price access, CDMOs with US fill-finish capacity, telehealth and pharmacy distribution channels. Losers: Novo Nordisk, manufacturers whose obesity assets read out behind tirzepatide, payers absorbing volume growth at lower unit prices.
Consumer. Oral Wegovy launched 2026-01-05 and passed 2 million prescriptions by early May 2026; Q2 2026 oral Wegovy sales were about $494m (DKK 3.2bn). Foundayo launched 2026-04-09 and recorded $98m in Q2 2026.
Regulatory. Very high. MFN agreements, Section 232 tariff exemptions, and the inclusion of semaglutide in Medicare negotiation cycle 2 (prices effective 2027-01-01) all now set the price directly.
Geography. US, EU, DK, CN, JP, GLOBAL

Risks and counter-forces

• Volume growth may not offset price compression for the second-place franchise
• [HEALTH-CLAIM] long-term safety and discontinuation data in non-trial populations remain thinner than trial data
• supply and manufacturing scale-up execution risk on oral formulations

Counter-trends. Medicare and Medicaid price-setting compressing net realised price, generic semaglutide entry outside the US from January 2026, payer utilisation management and coverage carve-outs for weight management

Score breakdown

⚠ Evidence-capped. Raw score 98.8 reduced to 94.0 by the evidence ceiling. The magnitude may be real; the sourcing does not yet support asserting it.

Stage mainstream · Direction accelerating · Horizon Immediate (0–12 months) · Reading: Act on it

What to watch next

• T-06-02 Most-favoured-nation pricing becomes the operative US drug-pricing regime
• T-06-03 Medicare negotiation crosses into Part B and captures semaglutide
• T-06-09 Generic semaglutide arrives outside the US, starting in Canada
• T-06-14 Oral incretins reset the manufacturing and distribution economics of obesity care

Sources

1. Lilly climbs, Novo falls as obesity drug battle intensifies — BioPharma Dive, 2026-08-05. Tier B. https://www.biopharmadive.com/news/lilly-novo-earnings-2q-2026-wegovy-pill-foundayo-obesity/827027/
2. Federal Update: Trump Administration Announces Deal to Bring Most-Favored-Nation Pricing to GLP-1s — Academy of Managed Care Pharmacy (AMCP), 2025-11-06. Tier B. https://www.amcp.org/letters-statements-analysis/federal-update-trump-administration-announces-deal-bring-most-favored-nation-pricing-glp-1s
3. Novo hikes guidance on Wegovy pill's fast sales start — BioPharma Dive, 2026-05-06. Tier B. https://www.biopharmadive.com/news/novo-nordisk-wegovy-pill-sales-prescriptions-q1-2026/819418/

Generated from record T-06-01 via the canonical article template (18-editorial-formats.md). Research date 2026-09-15. Scores per 14-scoring-framework.md. Forecasts are conditional, never certainties.

More research in this sector · Explore trend records